Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2025-03-17 00:00:00 ET · period of report 2025-03-13 · accession 0001415889-25-008275 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-03-17 | 2025-03-13 | MLYS | Samsara BioCapital, L.P. | 10% | P - Purchase | $13.50 | +600.0K | 5.67M | +12% | +$8.10M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-13 | P | A | 600,000 | $13.50 | 5,674,916 | I By Samsara BioCapital, L.P. | — | — | (F1) Securities are directly held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein. |